


CLAIMS

1. 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone of formula
 5 (I), or a pharmaceutically acceptable salt thereof,



(I)

2. A compound of formula (I) according to claim 1 which is a hydrate form of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone.
 10
3. A compound of formula (I) according to claim 2 which is 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone monohydrate.
 15
4. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.
5. A compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment related to neuroleptic therapy, Mild Cognitive impairment (MCI), impulsivity, Attention-Deficit Hyperactivity Disorder (ADHD), Parkinson's disease and other movement disorders, dystonia,
 20

Parkinson's dementia, Huntington's disease, dementia with Lewy Body, Alzheimer's disease drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

5 6. A compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof for use in the treatment of Parkinson's disease and other movement disorders, Alzheimer's disease, or cognitive and negative symptoms in schizophrenia.

10 7. A pharmaceutical composition comprising a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

15 8. Use of an effective amount of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and/or prevention of cognitive and negative symptoms in schizophrenia, cognitive impairment related to neuroleptic therapy, Mild Cognitive impairment (MCI), impulsivity, Attention-Deficit Hyperactivity Disorder (ADHD), Parkinson's disease and other movement disorders, dystonia, Parkinson's dementia, 20 Huntington's disease, dementia with Lewy Body, Alzheimer's disease drug addiction, sleep disorders, apathy, traumatic spinal cord injury or neuropathic pain.

25 9. Use of an effective amount of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of Parkinson's disease and other movement disorders, Alzheimer's disease, or cognitive and negative symptoms in schizophrenia.